Nuvectis Pharma Inc develops targeted small molecule therapeutics for genetically defined cancer patient populations, focusing on conditions with significant unmet medical needs. Its pipeline includes NXP800 and NXP900, which aim to provide effective treatment options for specific cancer types, such as ARID1a-mutated ovarian cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers have limited effective treatment options, especially when driven by specific genetic mutations or when patients develop resistance to existing therapies. This is particularly true for cancers like ARID1a-mutated ovarian cancer, where new, targeted approaches are needed to improve patient outcomes.
Solution
Nuvectis Pharma is developing small molecule therapeutics designed to target genetically defined cancer populations with unmet medical needs. Their pipeline includes NXP800, which is currently in Phase 1b clinical trials for platinum-resistant ARID1a-mutated ovarian cancer, and NXP900, in Phase 1a dose escalation studies, demonstrating robust pharmacodynamic response and acceptable safety at clinically relevant doses. These therapies aim to provide more effective and personalized treatment options by addressing the underlying genetic drivers of specific cancers. Preclinical data also supports NXP900's clinical development strategy as a single agent in biomarker-targeted cancers and in combination with market-leading therapies to overcome resistance in NSCLC.
Target Audience
The primary target audience includes patients with genetically defined cancers, such as ARID1a-mutated ovarian cancer, and the oncologists who treat them.
Features
- NXP800: A targeted therapy in Phase 1b clinical trials for ARID1a-mutated ovarian cancer.
- NXP900: A small molecule therapeutic in Phase 1a dose escalation studies, with data presented at the 2025 AACR conference demonstrating robust pharmacodynamic response and acceptable safety.
- Focus on precision medicine: Developing treatments for cancers with specific genetic mutations.
- Clinical data: NXP800 has demonstrated single-agent activity in interim data.
- Preclinical studies: NXP900 shows promise as a single agent and in combination therapies to overcome resistance in NSCLC.